Laxxon optimises drug delivery thanks to a patented, innovative 3D screen printing process

The tech­nol­ogy com­pany Laxxon Med­ical GmbH is set­tling in Jena and will in future develop and man­u­fac­ture inno­v­a­tive med­i­cines here on the basis of a spe­cial 3D screen print­ing process. An addi­tive man­u­fac­tur­ing process enables the pro­duc­tion of multi-lay­ered phar­ma­ceu­ti­cal appli­ca­tion forms such as tablets. With this tech­nol­ogy, tablets can be pro­vided with geo­met­ric struc­tures that enable the dis­tri­b­u­tion of one or more active phar­ma­ceu­ti­cal ingre­di­ents. This makes it pos­si­ble, for exam­ple, to achieve a delayed and, above all, con­sis­tent release of the active ingre­di­ents in the body over a longer period of time. On the one hand, this serves to improve the effec­tive­ness for the ben­e­fit of patients, and on the other hand, this patented process offers the phar­ma­ceu­ti­cal indus­try com­pletely new prod­uct devel­op­ment and man­u­fac­tur­ing approaches.
The 3D screen print­ing process has fur­ther advan­tages: It enables both the pro­duc­tion of very small quan­ti­ties, as required in clin­i­cal research, for exam­ple, and the mass pro­duc­tion of med­i­cines nec­es­sary for the phar­ma­ceu­ti­cal indus­try. In addi­tion, this spe­cial process makes it pos­si­ble to cre­ate a coun­ter­feit-proof “water­mark” inside the tablet to pro­tect against coun­ter­feit med­i­cines, some­thing that has been impos­si­ble with con­ven­tional man­u­fac­tur­ing processes. This could be a sig­nif­i­cant con­tri­bu­tion to pro­tec­tion against coun­ter­feit med­i­cines. Coun­ter­feit med­i­cines not only rep­re­sent a con­sid­er­able health risk for patients, they also cause annual dam­age to the phar­ma­ceu­ti­cal indus­try in Europe amount­ing to approx­i­mately EUR 10 bil­lion. In sum­mary, it can be said that Laxxon’s 3D screen print­ing process has con­sid­er­able poten­tial to quickly achieve high mar­ket shares with the help of this inno­va­tion. The poten­tial is jus­ti­fied in par­tic­u­lar by the fact that in the next 10 years more than 100 drugs with an annual sales vol­ume of USD 150 bn will lose their patent pro­tec­tion world­wide. The inter­est on the part of the indus­try to set itself apart from the com­pe­ti­tion through prod­uct improve­ments is cor­re­spond­ingly high.

bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t) has joined Laxxon Med­ical as lead investor through the Thuringian Start-up Fund (TSF) together with other pri­vate and insti­tu­tional investors. Kevin Reeder, Man­ag­ing Direc­tor of bm|t, states: “Laxxon’s deci­sion to choose Jena as the R&D nucleus for their extremely high-poten­tial project con­firms the Thuringian uni­ver­sity city as an excel­lent tech­no­log­i­cal loca­tion. Laxxon and the 3D screen print­ing tech­nol­ogy will sig­nif­i­cantly strengthen Jena’s tech­nol­ogy and life sci­ence cluster.”
The man­ag­ing direc­tors of Laxxon Med­ical GmbH, Prof. Dr. A. Schnee­berger and K. Kühne, are par­tic­u­larly pleased about the very good and direct coop­er­a­tion oppor­tu­ni­ties with the var­i­ous inter­dis­ci­pli­nary insti­tutes of the Uni­ver­sity of Jena. Their know-how in poly­mer devel­op­ment and mate­ri­als research as well as their tech­ni­cal equip­ment rep­re­sent a con­sid­er­able loca­tional advan­tage for Laxxon, which was also a deci­sive fac­tor in the company’s deci­sion to set­tle here.

About Laxxon Medical

Laxxon Med­ical GmbH, based in Jena, Ger­many, is a sub­sidiary of Laxxon Med­ical AG, domi­ciled in Zurich (CH), and a sis­ter com­pany of Laxxon Med­ical Corp., domi­ciled in New York (USA). Laxxon Med­ical spe­cialises in the prod­uct devel­op­ment and man­u­fac­ture of phar­ma­ceu­ti­cals using the 3D screen print­ing process. The inter­na­tional phar­ma­ceu­ti­cal mar­ket is to be addressed through these companies.

About bm|t

bm|t, based in Erfurt, is a sub­sidiary of the Thüringer Auf­baubank and the lead­ing address for invest­ments in Thuringia. The bm|t cur­rently man­ages eight funds with a total vol­ume of around EUR 320 mil­lion, which invest in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of com­pany devel­op­ment — both in the start-up and growth phases or in com­pany suc­ces­sion situations.

For further information

Laxxon Med­ical GmbH
Pas­cal Zeymer
Busi­ness Admin­is­tra­tion Manager
info@laxxon-medical.com